SCHEDULE 13G/A: BlackRock Discloses 15.8% Passive Stake in Alkermes plc
Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 15.8% passive beneficial ownership stake in Alkermes plc as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 25,638,477 shares of Alkermes plc common stock.
- This represents 15.8% of Alkermes plc's outstanding common stock.
- The filing is an Amendment No. 13 to a Schedule 13G, indicating an ongoing disclosure of a significant passive stake.
- BlackRock holds sole voting power over 25,364,123 shares and sole dispositive power over 25,638,477 shares.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Alkermes plc.
- BlackRock Fund Advisors, a subsidiary of BlackRock, Inc., beneficially owns 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing a passive ownership stake. It contains no positive or negative information about the issuer's performance or outlook, nor does it suggest any strategic intent by the investor beyond ordinary course of business.
Positives
- BlackRock's significant and continued passive stake of 15.8% in Alkermes plc suggests a long-term investment perspective and confidence in the company's fundamentals by a major institutional investor.
- The filing confirms that BlackRock's holding is for investment purposes in the ordinary course of business, not for control, which can provide stability to the company's governance structure.
Risks
- The filing explicitly states that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating risks associated with activist investor intervention from BlackRock.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Alkermes plc's future performance or BlackRock's future investment intentions beyond the passive nature of the holding.
Management Comments
- BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing is a routine disclosure by BlackRock, Inc., one of the world's largest asset managers, indicating its passive investment stake in Alkermes plc. Such filings are common for large institutional investors that cross significant ownership thresholds, reflecting their portfolio management activities rather than specific strategic moves related to the issuer's operations. Alkermes plc operates in the pharmaceutical industry, and BlackRock's stake signifies its inclusion in various investment funds and portfolios managed by BlackRock.
Comparison to Industry Standards
- As a Schedule 13G filing, this document primarily serves as a regulatory disclosure of a passive ownership stake by a large institutional investor. It does not provide performance metrics of Alkermes plc that would allow for direct comparison to industry standards or specific comparable companies.
- BlackRock's 15.8% stake is a significant passive holding, typical for a major asset manager like BlackRock which often holds substantial positions across a wide range of publicly traded companies as part of its index-tracking or actively managed funds.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a passive investment approach.
- Management: Reassures management that the large stake is not intended for control or activist intervention.
Next Steps
- BlackRock, Inc. will continue to hold its shares in Alkermes plc in the ordinary course of business.
- BlackRock, Inc. will file further amendments to Schedule 13G if there are material changes to its beneficial ownership or investment intent.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney revoked by the new one. |
| 2025-01-21 | Date of the new Power of Attorney executed by BlackRock, Inc. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-04-28 | Date the Schedule 13G/A was signed by BlackRock, Inc. |
Keywords
BlackRock, Alkermes plc, Schedule 13G, beneficial ownership, institutional investor, common stock, passive investment, pharmaceutical, biotechnology, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.